诺诚健华BCL2抑制剂拟纳入突破性治疗品种

药渡2025-04-30

4月29日，中国国家药监局药品审评中心（CDE）官网最新公示，诺诚健华申报的1类新药ICP-248片拟纳入突破性治疗品种，用于既往接受过免疫化疗和布鲁顿氏酪氨酸激酶抑制剂（BTKi）治疗的复发/难治性套细胞淋巴瘤（r/r MCL）患者。公开资料显示，这是诺诚健华研发的BCL2抑制剂。截图来源：CDE官网ICP-248（mesutoclax）是一款新型口服高选择性BCL2抑制剂。BCL2是细胞凋亡...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531749301?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-30 07:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2531749301","market":"sh","top_or_hot":-1,"title":"诺诚健华BCL2抑制剂拟纳入突破性治疗品种","media":"药渡","content":"<div>\n<p>4月29日，中国国家药监局药品审评中心（CDE）官网最新公示，诺诚健华申报的1类新药ICP-248片拟纳入突破性治疗品种，用于既往接受过免疫化疗和布鲁顿氏酪氨酸激酶抑制剂（BTKi）治疗的复发/难治性套细胞淋巴瘤（r/r MCL）患者。公开资料显示，这是诺诚健华研发的BCL2抑制剂。截图来源：CDE官网ICP-248（mesutoclax）是一款新型口服高选择性BCL2抑制剂。BCL2是细胞凋亡...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺诚健华BCL2抑制剂拟纳入突破性治疗品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺诚健华BCL2抑制剂拟纳入突破性治疗品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-30 07:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b><strong>药渡</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月29日，中国国家药监局药品审评中心（CDE）官网最新公示，诺诚健华申报的1类新药ICP-248片拟纳入突破性治疗品种，用于既往接受过免疫化疗和布鲁顿氏酪氨酸激酶抑制剂（BTKi）治疗的复发/难治性套细胞淋巴瘤（r/r MCL）患者。公开资料显示，这是诺诚健华研发的BCL2抑制剂。截图来源：CDE官网ICP-248（mesutoclax）是一款新型口服高选择性BCL2抑制剂。BCL2是细胞凋亡...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688428","symbol_name":"诺诚健华","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b","article_id":"2531749301","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430084621a6ce0a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2531749301","pubTimestamp":1745969531,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公开资料显示，这是诺诚健华研发的BCL2抑制剂。此外，诺诚健华的血液瘤管线也能发挥协同效应，尤其是BTK和BCL2抑制剂的联用有望为血液瘤患者带来更大获益。本次ICP-248片拟纳入突破性治疗品种的适应症为：既往接受过免疫化疗和BTK抑制剂治疗的r/r MCL患者。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688428":"诺诚健华","09969":"诺诚健华","BK0239":"医药制造"},"translate_title":"InnoCare BCL2 inhibitor intends to be included in breakthrough therapeutic varieties","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":0.9},"content_text":"4月29日，中国国家药监局药品审评中心（CDE）官网最新公示，诺诚健华申报的1类新药ICP-248片拟纳入突破性治疗品种，用于既往接受过免疫化疗和布鲁顿氏酪氨酸激酶抑制剂（BTKi）治疗的复发/难治性套细胞淋巴瘤（r/r MCL）患者。公开资料显示，这是诺诚健华研发的BCL2抑制剂。截图来源：CDE官网ICP-248（mesutoclax）是一款新型口服高选择性BCL2抑制剂。BCL2是细胞凋亡通路的重要调控蛋白，其表达异常与多种恶性血液肿瘤的发生发展相关。该产品通过选择性抑制BCL2蛋白，恢复肿瘤细胞凋亡，从而抑制肿瘤生长和扩散。根据诺诚健华公开资料介绍，ICP-248是该公司在血液瘤领域的重要产品，他们正全力推进ICP-248在全球开展的多项临床试验，包括治疗CLL/SLL在内的非霍奇金淋巴瘤，以及急性髓性白血病（AML）等。此外，诺诚健华的血液瘤管线也能发挥协同效应，尤其是BTK和BCL2抑制剂的联用有望为血液瘤患者带来更大获益。今年2月，诺诚健华宣布ICP-248联合BTK抑制剂奥布替尼一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）已经在中国获批注册性3期临床试验。本次ICP-248片拟纳入突破性治疗品种的适应症为：既往接受过免疫化疗和BTK抑制剂治疗的r/r MCL患者。诺诚健华此前已经公布了该产品的早期临床研究结果，共25名患者完成给药，6名RP2D剂量患者完成评估，包含r/r MCL和CLL/SLL患者。结果显示，该产品在100mg剂量下患者全部达到客观缓解，ORR为100%，CRR为50%，33%的受试者检测不到的微小残留病灶。该产品还表现出优秀的药代动力学特征，安全性、耐受性良好。参考资料：[1]中国国家药监局药品审评中心（CDE）官网.Retrieved Apr 29，2025, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c[2]诺诚健华多项肿瘤管线数据在2024年欧洲血液学协会年会上公布. RetrievedJuly 14, 2024, fromhttps://mp.weixin.qq.com/s/8Xv7VANL7Tp5dxKQBn1PLA[3]诺诚健华BCL2抑制剂ICP-248联合奥布替尼一线治疗CLL/SLL的注册性III期临床试验获CDE批准.Retrieved Feb 17，2025, from  https://mp.weixin.qq.com/s/oRpqh22AWomeVT__kx5a6g内容来源：医药观澜","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531749301","isCrawlerRequest":true}